| HOME >> MEDICINE >> TECHNOLOGY |
49810 %5 %Urology/Women's Health
371
3545 %3 %Neuromodulation
245
21912 %12 %Electrophysiology
110
111(1)%(2)%Subtotal Core Businesses5,6635,5522 %(1)%Divested Businesses
111
252N/AN/AWorldwide$ 5,774$ 5,804(1)%(4)%Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.
An explanation of the Company's use of these non-GAAP financial measures is provided at the end of this document.
BOSTON SCIENTIFIC CORPORATIONNON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS
(Unaudited)Q3 2011 Net Sales as compared to Q3 2010ChangeEstimatedAs ReportedConstantImpact ofCurrencyCurrencyForeignin millions
BasisBasisCurrencyUnited States$
(87)$
(87)EMEA
38
9
$
29Japan
22
0
22Inter-Continental
30
15
15International902466Subtotal Core Businesses3(63)66Divested Businesses
(45)
(45)
0Worldwide$
(42)$
(108)$Q3 2011 Net Sales as compared to Q3 2010ChangeEstimatedAs ReportedConstantImpact ofCurrencyCurrencyForeignin millions
BasisBasisCurrencyInterventional Cardiology
$
(1)
$
(25)
$
24Cardiac Rhythm Management
(47)
(65)
18Endoscopy
29
16
13Peripheral Interventions
15
7
8Urology/Women's Health
2
0
2Neuromodulation
5
5
0Electrophysiology
0
(1)
1Subtotal Core Businesses3(63)66Divested Businesses
(45)
(45)
0Worldwide$
(42)$
(108)$An explanation of the Company's use of these non-GAAP financial measures is provided at the end of this document.
BOSTON SCIENTIFIC CORPORATIONNON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS
(Unaudited)Q3 2011 YTD Net Sales as compared to Q3 2010 YTDChangeEstimatedAs ReportedConstantImpact ofCurrencyC
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2010 PR Newswire. All rights reserved |